Skip to content
The Department of Neurology has a long and dynamic legacy of promoting diversity and inclusion in the workplace and health care setting.
Contact our scheduling team to make an in-person or Virtual Visit appointment
Learn about our Adult Neurology and Child Neurology Residency Programs.
Clinical trials are a key component of the research mission of the Department of Neurology at CUIMC
Showing 11 - 20 of 260 results.
Claassen, MD, FNCS, Professor of Neurology, conducted a study that could help doctors to identify patients with brain injuries, in seemingly unresponsive states, who are more likely to recover
Study led by Claassen, MD, FNCS, Professor of Neurology, suggests that patients with hidden consciousness can hear & comprehend verbal commands, but they cannot carry out them out
New study lead by Jan Claassen, MD, FNCS, Professor of Neurology and Chief of Critical Care and Hospitalist Neurology at NYP/CUIMC, has identified brain injuries that may underlie hidden consciousness
Carol M. Troy, MD, PhD, Professor of Pathology & Cell Biology and Neurology at CUMC, discusses, based on a new study, how eye drops could be more effective in treating retinal vein occlusion
Two inaugural awards in the field of neurodegeneration were announced today as part of the Carol and Gene Ludwig Center for Research on Neurodegeneration.
Dr. Lawrence S. Honig, Professor of Neurology at the CUIMC, comments on the significance of Food and Drug Administration approval of the Alzheimer’s disease drug, Lecanemab
Mitchell S.V. Elkind, MD, MS, MPhil, Professor of Neurology & Epidemiology, comments on the new study & recommendation of taking daily baby aspirin to help prevent first-time heart attack or stroke
Lawrence S. Honig, MD, PhD, Professor of Neurology at the CUIMC, an investigator for the study that led to the FDA’s approval of Leqembi expresses his opinions about the new Alzheimer’s Disease drug
Joshua Z. Willey, MD, Associate Professor of Neurology at the CUIMC, comments on the risk-benefit of using aspirin by patients with no heart attack or stroke history
Andrew B. Lassman, MD, Professor of Neurology & Associate Dean of Clinical Trials at Columbia University, talks about the importance of enrolling a diverse population of subjects in clinical trials